Want to see ALDX full AI Analyst Report?
Top Page
Aldeyra Therapeutics
(NASDAQ:ALDX)
Select Model
Select Model
Rating:42Neutral
Price Target:
$0.89
▼(-42.84% Downside)
Action:Reiterated
Date:10/06/26
ALDX scores low primarily due to weak financial performance (pre-revenue losses and persistent cash burn with reduced TTM visibility) and bearish technicals (below major moving averages with negative MACD). Valuation is hard to support given negative earnings and no dividend, while the recent headquarters lease is a modestly positive operational signal but not enough to offset the core risks.
Positive Factors
Regulatory persistence and extended runway
The company is continuing structured regulatory engagement for reproxalap rather than abandoning the program after the Complete Response Letter. The extended projected runway provides additional time to pursue review, refine the application, and preserve strategic options without an immediate liquidity deadline.
Negative Factors
Pre-revenue business with recurring losses
The absence of demonstrated revenue means Aldeyra currently lacks an established commercial engine to fund research, development, or corporate expenses. Recurring operating and net losses leave future financial progress dependent on successful product development, approval, and eventual market adoption.
Read all positive and negative factors
Positive Factors
Negative Factors
Regulatory persistence and extended runway
The company is continuing structured regulatory engagement for reproxalap rather than abandoning the program after the Complete Response Letter. The extended projected runway provides additional time to pursue review, refine the application, and preserve strategic options without an immediate liquidity deadline.
Read all positive factors
Aldeyra Therapeutics (ALDX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$55.28M
Dividend YieldN/A
Average Volume (3M)1.42M
Price to Earnings (P/E)―
Beta (1Y)2.99
Revenue GrowthN/A
EPS Growth54.84%
CountryUS
Employees6
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.39
Shares Outstanding60,326,420
10 Day Avg. Volume3,003,189
30 Day Avg. Volume1,417,501
Financial Highlights & Ratios
PEG Ratio0.23
Price to Book (P/B)7.03
Price to Sales (P/S)0.00
P/FCF Ratio-9.33
Enterprise Value/Market Cap1.51
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.25K
Enterprise Value/Ebitda-3.91
Forecast
1Y Price Target
$2.00Price Target Upside29.03% Upside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)-0.34
Revenue Forecast (FY)$1.25M
Aldeyra Therapeutics Business Overview & Revenue Model
Company Description
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinica...
Aldeyra Therapeutics Financial Statement Overview
Summary
Income Statement
9
Very Negative
Balance Sheet
46
Neutral
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -66.60K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -21.37M | -31.69M | -53.68M | -35.21M | -60.07M | -55.77M |
| Net Income | -23.05M | -33.85M | -55.85M | -37.54M | -62.02M | -57.78M |
Balance Sheet | ||||||
| Total Assets | 47.54M | 72.06M | 104.61M | 148.33M | 181.29M | 233.14M |
| Cash, Cash Equivalents and Short-Term Investments | 45.09M | 70.04M | 101.15M | 142.82M | 174.30M | 229.79M |
| Total Debt | 143.45K | 15.53M | 15.30M | 15.66M | 16.08M | 15.86M |
| Total Liabilities | 9.66M | 27.81M | 33.60M | 28.53M | 30.28M | 27.40M |
| Stockholders Equity | 37.89M | 44.25M | 71.00M | 119.80M | 151.01M | 205.74M |
Cash Flow | ||||||
| Free Cash Flow | -22.04M | -33.35M | -43.21M | -30.33M | -56.65M | -42.56M |
| Operating Cash Flow | -22.02M | -33.35M | -43.21M | -30.33M | -56.64M | -42.56M |
| Investing Cash Flow | 40.98M | 47.74M | -44.92M | 30.00M | -29.95M | -7.81K |
| Financing Cash Flow | -15.11M | 1.12M | -171.42K | -1.27M | 1.22M | 194.50M |
Aldeyra Therapeutics Technical Analysis
Negative
1.55
Price Trends
1.40
Negative
1.61
Negative
2.57
Negative
Market Momentum
-0.14
Positive
29.95
Positive
14.22
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ALDX, the sentiment is Negative. The current price of 1.55 is above the 20-day moving average (MA) of 1.22, above the 50-day MA of 1.40, and below the 200-day MA of 2.57, indicating a bearish trend. The MACD of -0.14 indicates Positive momentum. The RSI at 29.95 is Positive, neither overbought nor oversold. The STOCH value of 14.22 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ALDX.
Aldeyra Therapeutics Risk Analysis
Aldeyra Therapeutics disclosed 89 risk factors in its most recent earnings report. Aldeyra Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Aldeyra Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | $1.44B | 10.38 | -109.40% | ― | ― | ― | |
54 Neutral | $397.35M | -9.23 | 21.48% | ― | ― | 33.25% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $760.59M | -7.05 | -89.38% | ― | ― | -108.75% | |
44 Neutral | $89.38M | -0.39 | -242.28% | ― | ― | 21.31% | |
42 Neutral | $55.28M | -2.37 | -53.14% | ― | ― | 54.84% | |
42 Neutral | $118.77M | -2.02 | 72.64% | ― | 51.98% | 17.68% |
* Healthcare Sector Average
ALDX
Aldeyra Therapeutics
0.92
-4.33
-82.55%
OMER
Omeros
19.83
15.64
373.27%
GALT
Galectin Therapeutics
3.94
-1.16
-22.75%
FHTX
Foghorn Therapeutics
2.00
-2.29
-53.38%
CADL
Candel Therapeutics
9.94
3.47
53.63%
NMRA
Neumora Therapeutics, Inc.
0.48
-1.39
-74.46%
Aldeyra Therapeutics Corporate Events
Business Operations and StrategyLegal Proceedings
Aldeyra Pursues FDA Dispute Over Dry Eye Drug
Neutral
Sep 29, 2026
On September 25, 2026, Aldeyra Therapeutics held a Type D meeting with the U.S. Food and Drug Administration regarding reproxalap for the treatment of dry eye disease, following a March 16, 2026 Complete Response Letter that denied approval of its...
Business Operations and Strategy
Aldeyra Therapeutics Leases New Concord Headquarters Space
Positive
Jul 30, 2026
On July 28, 2026, Aldeyra Therapeutics executed a lease agreement with Bradford Street, L.L.C. for approximately 4,067 square feet of office space at 23 Bradford Street in Concord, Massachusetts. The lease term runs from September 1, 2026 through ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.